Literature DB >> 8080943

Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA).

R A Hiatt1, K Tolan, C P Quesenberry.   

Abstract

Renal cell carcinoma has been linked to hypertension and antihypertensive medications. We investigated the association between renal cell carcinoma and the use of thiazide in a case-control study of 167 men and 90 women. Subjects were members of the Kaiser Permanente Medical Care Program in northern California (United States) who had taken a multiphasic health check-up from 1964 through 1988 and who were evaluated for cancer until the end of 1989. Control subjects received the same check-up, were matched by gender, year of check-up, and age at check-up, and had to be in the health plan until the date on which renal cell carcinoma was diagnosed. Data on known and potential risk factors, including hypertension, body mass index (BMI), and smoking status, were collected from the record of the check-up. Thiazide use was abstracted from the medical chart, which was reviewed from the date of the first entry until the date on which the cancer was diagnosed or the equivalent date for control subjects. The mean follow-back to check-up was 11.3 years. Among women, we found a significantly elevated risk of 4.0 (95 percent confidence interval [CI] 1.5-10.8) associated with ever having used thiazide after we adjusted for smoking, BMI, hypertension, and history of kidney infection at check-up. We did not find a statistically significantly elevated risk in men. Smoking was related to renal cell carcinoma in men (odds ratio [OR] 2.5, CI = 1.1-5.4) for those who smoked at least one pack per day compared with those who had never smoked, but was not related in women.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080943     DOI: 10.1007/bf01804982

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  18 in total

1.  Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists.

Authors:  G E Fraser; R L Phillips; W L Beeson
Journal:  Int J Epidemiol       Date:  1990-12       Impact factor: 7.196

2.  Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma.

Authors:  M C Yu; T M Mack; R Hanisch; C Cicioni; B E Henderson
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

3.  Risk factors for renal cell carcinoma: results of a population-based case-control study.

Authors:  N Kreiger; L D Marrett; L Dodds; S Hilditch; G A Darlington
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

4.  Ultrastructure of renal adenoma.

Authors:  P Holm-Nielsen; T S Olsen
Journal:  Ultrastruct Pathol       Date:  1988 Jan-Feb       Impact factor: 1.094

5.  Smoking and renal cell carcinoma.

Authors:  C La Vecchia; E Negri; B D'Avanzo; S Franceschi
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

6.  Diuretics may increase risk of renal cell carcinoma.

Authors:  A Mellemgaard; H Møller; J H Olsen
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

7.  Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions.

Authors:  N R Asal; J R Geyer; D R Risser; E T Lee; S Kadamani; N Cherng
Journal:  Cancer Detect Prev       Date:  1988

8.  The association of blood pressure with cancer incidence in a prospective study.

Authors:  J S Grove; A Nomura; R K Severson; G N Stemmermann
Journal:  Am J Epidemiol       Date:  1991-11-01       Impact factor: 4.897

9.  A population--based case--control study of renal cell carcinoma.

Authors:  J K McLaughlin; J S Mandel; W J Blot; L M Schuman; E S Mehl; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1984-02       Impact factor: 13.506

10.  Risk of kidney cancer among patients using analgesics and diuretics: a population-based cohort study.

Authors:  P Lindblad; J K McLaughlin; A Mellemgaard; H O Adami
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

View more
  12 in total

Review 1.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 2.  Carcinogenicity of cardiovascular drugs.

Authors:  E Grossman; F H Messerli; U Goldbourt
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

3.  Antihypertensive medication use and risk of renal cell carcinoma.

Authors:  Joanne S Colt; Jonathan N Hofmann; Kendra Schwartz; Wong-Ho Chow; Barry I Graubard; Faith Davis; Julie Ruterbusch; Sonja Berndt; Mark P Purdue
Journal:  Cancer Causes Control       Date:  2017-02-21       Impact factor: 2.506

Review 4.  Nutrition and renal cell cancer.

Authors:  A Wolk; P Lindblad; H O Adami
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

5.  Alcohol intake and renal cell cancer risk: a meta-analysis.

Authors:  D Y Song; S Song; Y Song; J E Lee
Journal:  Br J Cancer       Date:  2012-04-19       Impact factor: 7.640

Review 6.  Antihypertensive therapy and cancer risk.

Authors:  D C Felmeden; G Y Lip
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

7.  Epidemiologic characteristics and risk factors for renal cell cancer.

Authors:  Loren Lipworth; Robert E Tarone; Lars Lund; Joseph K McLaughlin
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

Review 8.  Nonhormonal drugs and cancer.

Authors:  P D Stolley; S H Zahm
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

9.  Obesity and renal cell cancer--a quantitative review.

Authors:  A Bergström; C C Hsieh; P Lindblad; C M Lu; N R Cook; A Wolk
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

10.  Hypertension, obesity and their medications in relation to renal cell carcinoma.

Authors:  J M Yuan; J E Castelao; M Gago-Dominguez; R K Ross; M C Yu
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.